

Daftar Pustaka

- Abdel-Misih, S.R.Z., Bloomston, M. 2010. Liver Anatomy. *Surgical Clinics of North America*. 90 (2010) 643–653. doi:10.1016/j.suc.2010.04.017
- Anis, M. (2011) ‘Imaging of Hepatocellular Carcinoma: Practical Guide to Differential Diagnosis’, *liver.theclinics.com*, 15, pp. 335–352. doi: 10.1016/j.cld.2011.03.014.
- Arslanoglu, A., Chalian, H., Sodagari, F., Seyal, A. R., Töre, H. G., Salem, R., & Yaghmai, V. (2016). Threshold for enhancement in treated hepatocellular carcinoma on MDCT: Effect on necrosis quantification. *American Journal of Roentgenology*, 206(3), 536–543. <https://doi.org/10.2214/ajr.15.15339>
- Arslanoglu, A., Seyal, A.R., Sodagari, F., Sahin, A., Miller, F.H., Salem, R., Yaghmai, V. 2016. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. *American Journal of Roentgonology*. 2016; 207:W1–W11. DOI:10.2214/AJR.15.15490
- Bağırsakçı, E., Şahin, E., Atabey, N., Erdal, E., Guerra, V. and Carr, B. (2017). Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. *Oncology*, 93(2), pp.136-142. doi: 10.1159/000471807
- Bağırsakçı, E., Şahin, E., Atabey, N., Erdala, E., Guerra, V., Carr, B.I. (2017). Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. *Oncology*. DOI: 10.1159/000471807
- Bernardi, M., Maggioli, C., Zaccherini, G. (2012). Human albumin in the management of complications of liver cirrhosis. *Critical Care*. 2012, 16:211. DOI: 10.1007/978-3-642-25716-2
- Bernardi, M., Ricci, C. and Zaccherini, G. (2014). Role of Human Albumin in the Management of Complications of Liver Cirrhosis. *Journal of Clinical and Experimental Hepatology*, 4(4), pp.302-311. doi:10.1186/cc11218
- Bujang, M. A., & Baharum, N. (2016). Sample size guideline for Correlation Analysis. *World Journal of Social Science Research*, 3(1), 37. <https://doi.org/10.22158/wjssr.v3n1p37>
- Carr, B. I., & Guerra, V. (2013). Hepatocellular Carcinoma Size: Platelets, γ -Glutamyl Transpeptidase, and Alkaline Phosphatase. *Oncology*, 85(3), 153–159. doi:10.1159/000354416
- Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., ... Rapaccini, G. L. (2014). Significance of Platelet and AFP Levels and Liver Function Parameters for HCC Size and Survival. *The International Journal of Biological Markers*, 29(3), 215–223. doi:10.5301/jbm.5000064

- Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., Ludovico Rapaccini, G., Di Marco, M., Benvegnù, L., Zoli, M., Borzio, F., Caturelli, E., Chiaramonte, M., & Trevisani, F. (2014). Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. *Seminars in Oncology*, 41(2), 252–258. <https://doi.org/10.1053/j.seminoncol.2014.03.006>
- Chartampilas, E., Rafailidis, V., Georgopoulou, V., Kalarakis, G., Hatzidakis, A., & Prassopoulos, P. (2022). Current imaging diagnosis of hepatocellular carcinoma. *Cancers*, 14(16), 3997. <https://doi.org/10.3390/cancers14163997>
- Chernyak, V., Fowler, K. J., Kamaya, A., Kielar, A. Z., Elsayes, K. M., Bashir, M. R., Kono, Y., Do, R. K., Mitchell, D. G., Singal, A. G., Tang, A., & Sirlin, C. B. (2018). Liver imaging reporting and data system (li-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. *Radiology*, 289(3), 816–830. <https://doi.org/10.1148/radiol.2018181494>
- Cholankeril, G., Patel, R., Khurana, S., & Satapathy, S. K. (2017). Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. *World Journal of Hepatology*, 9(11), 533. doi:10.4254/wjh.v9.i11.533
- Ellis, H. 2011. Anatomy of the liver. *Surgery* : 29(12), pp. 589– 592. Elsevier Ltd. doi: 10.1016/j.mpsur.2011.09.012.
- Elsayes, K. M., Kielar, A. Z., Chernyak, V., Morshid, A., Furlan, A., Masch, W. R., Marks, R. M., Kamaya, A., Do, R. K. G., Kono, Y., Fowler, K. J., Tang, A., Bashir, M. R., Hecht, E. M., Jambhekar, K., Lyshchik, A., Rodgers, S. K., Heiken, J. P., Kohli, M., ... Sirlin, C. B. (2019). li-rads: A conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. *Journal of Hepatocellular Carcinoma*, Volume 6, 49–69. <https://doi.org/10.2147/jhc.s186239>
- El-Serag, H. B. and Rudolph, K. L. (2007) ‘Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis’, *Gastroenterology*, 132(7), pp. 2557–2576. doi: 10.1053/j.gastro.2007.04.061.
- Farazi, P. A. and DePinho, R. A. (2006) ‘Hepatocellular carcinoma pathogenesis: From genes to environment’, *Nat Rev Cancer*, 6(9), pp. 674–687. doi: 10.1038/nrc1934.
- Forner, A., Reig, M. and Bruix, J. (2018). Hepatocellular carcinoma. *The Lancet*, 391(10127), pp.1301-1314.
- Grandhi, M. S., Kim, A. K., Ronnekleiv-Kelly, S. M., Kamel, I. R., Ghasebeh, M. A. and Pawlik, T. M. (2016) ‘Hepatocellular carcinoma: From diagnosis to treatment’, *Surgical Oncology*. Elsevier Ltd, 25(2), pp. 74–85. doi: 10.1016/j.suronc.2016.03.002.

- Hennedige TP, Neo WT, Venkatesh SK. (2014) Imaging of malignancies of the biliary tract- an update. *Cancer Imaging*. Apr 22;14(1):14. doi: 10.1186/1470-7330-14-14. PMID: 25608662; PMCID: PMC4331820.
- Ho, S.Y., Liu, P.H., Hsu, C.Y., Hsia, C.Y., Lee, Y.H., Lee, R.C., *et al.* (2017). Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS ONE*. 12(7): e0180408.<https://doi.org/10.1371/journal.pone.018048>.
- Hoekstra, L.T., de Graaf, W., Nibourg, G.A.A., Heger, M., Bennink, R.J., Stiegre, B., *et al.* (2013). Physiological and Biochemical Basis of Clinical Liver Function Tests. *Annals of Surgery*. 2013;257: 27–36. DOI: 10.1097/SLA.0b013e31825d5d47
- Johnson, P.J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H.L., *et al.* (2014). Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. *Journal Clinical of Oncology*. 33:550-558. DOI: 10.1200/JCO.2014.57.9151
- Khalid, M.A., Achakzai, I.K., Hanif, F.M., Ahmed, S., Majid, Z., Luck, N.H. (2019). To determine the prognostic value of the albumin–bilirubin grade (ALBI) in patients underwent transarterial chemoembolization for unresectable hepatocellular carcinoma. *Gastroenterology and Hepatology From Bed to Bench*. 2019;12(2):110-115.
- Kulik, L., El-Serag, H.B. (2019). Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*. 2019;-:1 –15
- Kulkarni, N. M., Fung, A., Kambadakone, A. R., & Yeh, B. M. (2021). Computed tomography techniques, protocols, advancements, and future directions in liver diseases. *Magnetic Resonance Imaging Clinics of North America*, 29(3), 305–320. <https://doi.org/10.1016/j.mric.2021.05.002>
- Lee, C.-W., Tsai, H.-I., Lee, W.-C., Huang, S.-W., Lin, C.-Y., Hsieh, Y.-C., Kuo, T., Chen, C.-W., & Yu, M.-C. (2019). Normal alpha-fetoprotein hepatocellular carcinoma: Are they really normal? *Journal of Clinical Medicine*, 8(10), 1736. <https://doi.org/10.3390/jcm8101736>
- Li, Z., Tuteja, G., Schug, J., & Kaestner, K. H. (2012a). FOXA1 and FOXA2 are essential for sexual dimorphism in liver cancer. *Cell*, 148(1–2), 72–83. <https://doi.org/10.1016/j.cell.2011.11.026>
- Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018). Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. *Hepatology*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>

- McEvoy, S. H., McCarthy, C. J., Lavelle, L. P., Moran, D. E., Cantwell, C. P., Skehan, S. J., Gibney, R. G., & Malone, D. E. (2013). Hepatocellular carcinoma: Illustrated guide to systematic radiologic diagnosis and staging according to guidelines of the American Association for the study of liver diseases. *RadioGraphics*, 33(6), 1653–1668. <https://doi.org/10.1148/rg.336125104>
- Mendez-Sanchez, N., Qi, X., Vitek, L., Arrese, M. (2019). Evaluating an Outpatient With an Elevated Bilirubin. *American Journal of Gastroenterology*. 2019;114: 1185– 1188. <https://doi.org/10.14309/ajg.0000000000000036>
- Mittal, S. and El-Serag, H.B. (2013) ‘Epidemiology of hepatocellular carcinoma’, *Journal of Clinical Gastroenterology*, 47(Supplement 1). doi:10.1097/mcg.0b013e3182872f29.
- Padhya, K. T., Marrero, J. A. and Singal, A. G. (2013) ‘Recent advances in the treatment of hepatocellular carcinoma’, *Curr Opin Gastroenterol*, 29(3), pp. 285–292. doi: 10.1097/MOG.0b013e32835ff1cf.
- Peng, Y.F., Goyal, H., Xu, G.D. (2017). Serum bilirubin has an important role in multiple clinical applications. *Journal of Laboratory and Precision Medicine*. 2017;2:82. <http://dx.doi.org/10.21037/jlpm.2017.09.08>
- PN, A. *et al.* (2016) ‘Response evaluation of patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma with respect to tumour size, number of lesion, and alpha-fetoprotein (AFP) level’, *The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy*, 17(1), pp. 3–9. doi:10.24871/17120163-9.
- Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *Journal of Hepatology*, 76(3), 681–693. <https://doi.org/10.1016/j.jhep.2021.11.018>
- Richani, M., Kolly, P., Knoepfli, M., Herrmann, E., Zweifel, M., Tengg-Kobligk, H. von, ... Dufour, J.-F. (2016). Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. *Annals of Hepatology*, 15(1), 82–90. doi:10.5604/16652681.1184233
- Sanyal, A. J., Yoon, S. K. and Lencioni, R. (2010) ‘The Etiology of Hepatocellular Carcinoma and Consequences for Treatment’, *The Oncologist*, 15(Supplement 4), pp. 14–22. doi: 10.1634/theoncologist.2010-S4-14.
- Song, D.S. and Bae, S.H. (2012) “Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period,” *Clinical and Molecular Hepatology*, 18(3), p. 258. Available at: <https://doi.org/10.3350/cmh.2012.18.3.258>.
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: Globocan estimates of incidence